Synchronous lung adenocarcinoma in situ and type B2-B3 thymoma in a frozen hemithorax: a case report and multidisciplinary approach - Top-Institutions - MDSpire

Synchronous lung adenocarcinoma in situ and type B2-B3 thymoma in a frozen hemithorax: a case report and multidisciplinary approach

  • By

  • Chenglin Fan

  • Gaoyuan Sang

  • Ziyi Liang

  • Jialin Yu

  • Sixuan Song

  • Jingjun Zhu

  • Zhengzhe Xu

  • May 15, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Thoracic Oncology
    • Surgery
    • Radiation Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Thoracic Surgery
    • Thoracic Oncology

  • #3

    University Hospital of Pisa
    University Hospital of Pisa

    Pisa, Italy

    Key Differentiators

    • Oncology

  • #4

    Zhongnan Hospital of Wuhan University
    Zhongnan Hospital of Wuhan University

    Wuhan, China

    Key Differentiators

    • Oncology

  • #5

    Fudan University Shanghai Cancer Center
    Fudan University Shanghai Cancer Center

    Shanghai, China

    Key Differentiators

    • Oncology

Original Source(s)

Synchronous lung adenocarcinoma in situ and type B2-B3 thymoma in a frozen hemithorax: a case report and multidisciplinary approach

  • by Chenglin Fan, Gaoyuan Sang, Ziyi Liang, Jialin Yu, Sixuan Song, Jingjun Zhu, Zhengzhe Xu

  • May 15, 2026

Related Content

Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?

A systematic review and meta-analysis found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers, with the association appearing to be ...

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonge...

Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures

Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occ...